Active Collaborations

We actively collaborate with the pharmaceutical industry, aiming to identify new and more effective drugs. Such collaborations led to the development of a novel HTS assay for rapid monitoring of efficacy and toxicity of candidate anti-TB compounds within human macrophages.

Our research into the thiol-based mechanism used by mycobacteria to protect against nitric oxide damage led to a drug development program using nitric oxide as an antimicrobial agent. This was licensed out to two companies.

Within UBC


Centre for Tuberculosis Research UBC


Prof. Lawrence McIntosh – Department of Biochemistry

Prof. Joerg Gsponer – Department of Biochemistry & Molecular Biology

Prof. Michel Roberge – Department of Biochemistry & Molecular Biology

Prof. Raymond Andersen – Department of Chemistry

Prof. Horacio Bach –  Infectious Diseases


Dr. Jeffrey Chen – Vaccine and Infectious Disease Organization
University of Saskatchewan

Dr. David Kwan – Concordia University

Dr. Todd Lowary – University of Alberta


International Collaborations

Prof. Bill Jacobs – Albert Einstein College of Medicine – Images

Prof. Adrie Steyn – K-RITH, Kwazulu-Natal Research Institute for TB-HIV

Prof. Peter Imming – Pharmazeutische Chemie Institut fuer Pharmazie Martin-Luther-Universität Halle-Wittenberg

Industry Collaborations: *all industry collaborations are established under the WIPO agreement* 

GlaxoSmithKline Diseases of the Developing World
Tres Cantos Open Lab Images
Takeda Pharmaceuticals
Celgene Global Health, Drugs for Neglected Diseases Initiative